-

Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, 2024, at 1:30 p.m. PT.

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at: https://jpmorgan.metameetings.net/events/healthcare24/sessions/49500-organon/webcast?gpu_only=true&kiosk=true

About Organon
Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, X (formally known as Twitter) and Facebook.

Contacts

Media:

Karissa Peer
(614) 314-8094

Kate Vossen
(732) 675-8448

Investor:

Jennifer Halchak
(201) 275-2711

Alex Arzeno
(646) 430-2028

Organon & Co.

NYSE:OGN
Details
Headquarters: Jersey City, New Jersey, USA
CEO: Joseph Morrissey
Employees: 10,000
Organization: PUB

Release Summary
Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference, Tuesday January 9.
Release Versions

Contacts

Media:

Karissa Peer
(614) 314-8094

Kate Vossen
(732) 675-8448

Investor:

Jennifer Halchak
(201) 275-2711

Alex Arzeno
(646) 430-2028

Social Media Profiles
More News From Organon & Co.

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's NEXPLANON receives U.S. FDA sNDA approval for extended duration of use up to five years, including data for use in women with varying BMIs....

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters into agreement to expand access to a new, first-in-class treatment in certain European countries; builds on cardiovascular portfolio...

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's Interim CEO Joe Morrissey and CFO Matthew Walsh to participate in fireside chat at Piper Sandler Annual Healthcare Conference on December 3....
Back to Newsroom